May 7, 2024 – Page 10 – Goldea Capital

Orezone Provides Notice of Q1-2024 Results and Conference Call

Written by Customer Service on May 7, 2024. Posted in Public Companies.

VANCOUVER, British Columbia, May 07, 2024 (GLOBE NEWSWIRE) — Orezone Gold Corporation (TSX: ORE, OTCQX: ORZCF) (“Orezone”) will announce its first quarter 2024 results on May 13, 2024 after market close. A conference call and audio webcast to discuss the results will take place on Tuesday, May 14, 2024, at 8:00 am PT (11:00 am ET). Webcast Date: Monday, May 14, 2024 Time: 8:00 am Pacific time (11:00 am Eastern time) Please register for the webcast here: Orezone Q1-2024 Conference Call and Webcast Conference CallToll-free in U.S. and Canada: 1-800-715-9871International callers: +646-307-1963Event ID: 2084420 About Orezone Gold Corporation Orezone Gold Corporation (TSX: ORE OTCQX: ORZCF) is a West African gold producer engaged in mining, developing, and exploring its 90%-owned flagship Bomboré Gold Mine in Burkina...

SI-BONE Expands Portfolio with the Launch of New Offering for the iFuse Bedrock Granite Implant System and Completes Inaugural Surgical Procedures

Written by Customer Service on May 7, 2024. Posted in Public Companies.

SANTA CLARA, Calif., May 07, 2024 (GLOBE NEWSWIRE) — SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced the first cases completed with the smaller, 9.5 mm diameter, iFuse Bedrock Granite® Implant (Granite 9.5). When placed across the SI joint, the Granite implant provides sacroiliac fusion and spinopelvic fixation as a foundational element for multi-segment spinal fusion. This milestone for Granite 9.5 comes after 510(k) clearance in January 2024. The iFuse Bedrock Granite Implant System was awarded a Breakthrough Device Designation by the Food & Drug Administration and a New Technology Add-on Payment by the Centers for Medicare and Medicaid Services. Granite 9.5 may be more suitable for patients with smaller anatomy...

Model N Introduces New Rebate Enhancement, as Pharma Companies Prepare for Impact from the Inflation Reduction Act

Written by Customer Service on May 7, 2024. Posted in Public Companies.

New Medicare Part D inflation rebate enhancement helps pharma manufacturers manage pricing reforms SAN MATEO, Calif., May 07, 2024 (GLOBE NEWSWIRE) — Model N (NYSE: MODN), the leader in revenue optimization and compliance has introduced a critical product enhancement that supports evolving compliance needs around the Inflation Reduction Act (IRA). The company has introduced a new Medicare Part D inflation rebate-per-unit, ensuring pharma manufacturers remain compliant with impending IRA regulation and avoid significant revenue loss. “The Inflation Reduction Act introduces sweeping changes for drug pricing and Medicare programs, and our goal is to empower customers to stay ahead of these shifts,” said Suresh Kannan, Chief Product Officer at Model N. “As our life sciences customers prepare for new reforms and regulatory...

ALX Oncology Appoints Allison Dillon as Chief Business Officer

Written by Customer Service on May 7, 2024. Posted in Public Companies.

SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the appointment of Allison Dillon, Ph.D., as Chief Business Officer (“CBO”). “We are excited to welcome Allison to our leadership team in the midst of this promising growth period for our Company,” said Jason Lettmann, Chief Executive Officer of ALX Oncology. “For over 15 years, Allison has worked to develop and deliver novel oncology products to patients with cancer. With multiple clinical study readouts over the next 12 months, Allison’s deep oncology market expertise and impressive track record in executing portfolio, development, and commercial strategy will be vital in our endeavor...

Edible Garden Announces Product Development Agreement with Hermann Pickle Company

Written by Customer Service on May 7, 2024. Posted in Public Companies.

R&D partnership focused on next-generation fermented product development Strategy to leverage Edible Garden’s credibility in produce for new product expansion BELVIDERE, NJ, May 07, 2024 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), locally grown, organic, and sustainable produce and products, today announced that it has entered into a product development agreement (the “Agreement”) with Hermann Pickle Company LLC (“Hermann Pickles”), an industry leading company in the region that specializes in refrigerated kosher dill pickles, sauerkraut and fermented food products based in Garrettsville, Ohio. Under the Agreement, the parties intend to collaborate on the research and development of scalable commercial opportunities...

Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business

Written by Customer Service on May 7, 2024. Posted in Mergers And Acquisitions.

SALT LAKE CITY, May 07, 2024 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the reorganization of its European operations to better align company resources to its domestic opportunities while continuing to serve key biopharma partners and patients outside the United States. As part of the reorganization, Myriad signed a definitive agreement to sell its EndoPredict® business to Eurobio Scientific, a leading French group in in vitro medical diagnostics and life sciences. Myriad will also license Eurobio the right to sell Prolaris in vitro diagnostic kits outside the U.S. Myriad will license the rights to continue to produce and sell EndoPredict, as a Laboratory Developed Test (LDT), in the U.S. as part of Precise Oncology Solutions, its comprehensive suite...

Mimecast Closes Strongest Expansion Year on Record

Written by Customer Service on May 7, 2024. Posted in Earnings Releases And Operating Results.

Expands leadership team with appointment of Chris Wey as Chief Transformation Officer LEXINGTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) — Mimecast, a global cybersecurity company, capped a year of robust growth with the largest new and expansion revenue gains in the company’s history. Customers are responding positively to Mimecast’s strong product innovation and acquisition strategy. For example, the recently launched Cloud Integrated Email Security solution, designed to protect Microsoft 365 via robust API integration, has already onboarded customers in every global operating region. More than half of those customers have come through valued Managed Service Provider (MSP) partners. Additionally, the company has seen growth with its awareness training platform, and rapid adoption of its DMARC solution, which saw a 38% increase...

Great Lakes Reports First Quarter 2024 Results

Written by Customer Service on May 7, 2024. Posted in Earnings Releases And Operating Results.

First quarter net income of $21.0 millionFirst quarter adjusted EBITDA of $42.9 millionDredging backlog of $879.4 million at March 31, 2024 HOUSTON, May 07, 2024 (GLOBE NEWSWIRE) — Great Lakes Dredge & Dock Corporation (“Great Lakes” or the “Company”) (Nasdaq: GLDD), the largest provider of dredging services in the United States, today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights Revenue was $198.7 million Total operating profit was $31.5 million Net income was $21.0 million Adjusted EBITDA was $42.9 million Management Commentary Lasse Petterson, President and Chief Executive Officer commented, “Great Lakes ended the first quarter with strong financial results, including net income of $21.0 million and adjusted EBITDA of $42.9 million, which is the best adjusted...

Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights

Written by Customer Service on May 7, 2024. Posted in Earnings Releases And Operating Results.

Encouraging preliminary data announced from the NXP800 Phase 1b study in platinum resistant, ARID1a-mutated ovarian cancer, a program granted Fast Track Designation by the US FDA Data presented at the 2024 AACR demonstrate NXP900’s robust activity in non-small cell cancer cell lines Several clinical data updates expected in 2H 2024 FORT LEE, N.J., May 07, 2024 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the first quarter 2024 and provided an update on recent business progress. Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis,...

Global Ship Lease Announces First Quarter 2024 Earnings Release, Conference Call and Webcast

Written by Customer Service on May 7, 2024. Posted in Public Companies.

ATHENS, Greece, May 07, 2024 (GLOBE NEWSWIRE) — Global Ship Lease, Inc. (NYSE:GSL) (the “Company”), a containership charter owner, announced today that it will hold a conference call to discuss the Company’s results for the first quarter 2024 on Thursday, May 16, 2024 at 10:30 a.m. Eastern Time. The Company will issue financial results for the first quarter 2024 on Thursday, May 16, 2024, before the open of market trading. What: First Quarter 2024 Conference Call and Webcast When: Thursday, May 16, 2024 at 10:30 a.m. Eastern Time Where: There are two ways to access the conference call: Dial-in: (646) 307-1963 or (800) 715-9871; Event ID: 1926153Please dial in at least 10 minutes prior to 10:30 a.m. Eastern Time to ensure a prompt start to the call. Live Internet webcast and slide presentation:http://www.globalshiplease.com The...

Day: May 7, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice